
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions</strong></summary>
            <div>
                <ul><li>Authors: Douglas R. Morgan, MD, MPH, FACG et al.</li><li>Journal: American Journal of Gastroenterology</li><li>Publication Date: April 2025</li><li>DOI: https://doi.org/10.14309/ajg.0000000000003350</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the US 5-year survival rate for gastric cancer?</li><li>2.  Name three gastric premalignant conditions (GPMC).</li><li>3.  What is the dominant risk factor for noncardia gastric adenocarcinoma?</li><li>4.  How often is surveillance endoscopy recommended for individuals at high risk for GPMC progression?</li><li>5.  What is the primary outcome of interest in this clinical guideline?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>GC is a leading infection-associated cancer &amp; 4th leading cause of cancer-related mortality globally.</li><li>US considered low-incidence country, ASIR 6.5 per 100,000 person-years.</li><li>Specific US populations (immigrants, non-White) have 2–13 fold ↑ GC incidence.</li></ul>
                
        <details>
            <summary><strong>GC Disparities in the US</strong></summary>
            <div>
                <ul><li>GC ranks among top 8 causes of cancer death in US Hispanic &amp; Asian American populations.</li><li>By 2065, Asian &amp; Hispanic individuals will comprise ≈70% of US population.</li><li>H. pylori treatment is associated w/ reduced GC incidence in US populations.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Correa Cascade &amp; GPMC</strong></summary>
            <div>
                <ul><li>Gastric adenocarcinoma preceded by precancerous cascade: normal mucosa → chronic gastritis → AG → MAG → GIM → LGD/HGD → adenocarcinoma.</li><li>H. pylori dominant risk factor for noncardia gastric adenocarcinoma (75%–89% attributable risk).</li><li>AG, GIM, &amp; dysplasia constitute GPMC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Early Gastric Cancer (EGC)</strong></summary>
            <div>
                <ul><li>EGC defined as adenocarcinoma not invaded past submucosal layer.</li><li>Resection typically curative (&gt;95% 5-year overall survival).</li><li>Focus of guideline: diagnosis &amp; management of GPMC, noncardia gastric adenocarcinoma primary outcome.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>Presents ACG official recommendations on diagnosis, management, &amp; surveillance of GPMC in adults.</li><li>Supports clinical practice, suggests preferable approaches based on published literature.</li><li>GRADE process used to assess quality of evidence for each statement.</li></ul>
                
        <details>
            <summary><strong>GRADE System</strong></summary>
            <div>
                <ul><li>Quality of evidence: high, moderate, low, very low.</li><li>Strength of recommendation: strong (recommendations) or conditional (suggestions).</li><li>Narrative evidence summary provides definitions &amp; details supporting statements.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Literature Search</strong></summary>
            <div>
                <ul><li>Electronic search using MEDLINE, EMBASE, Cochrane Library through October 2023, updated August 2024.</li><li>Prioritized evidence from US populations; relied on non-US data when US data limited.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guideline Scope</strong></summary>
            <div>
                <ul><li>Beyond scope: hereditary GC syndromes, GIM of cardia, nonadenocarcinoma GC, MALT lymphoma, therapeutic management of GC, postdiagnostic management of GC other than H. pylori eradication.</li><li>First iteration; quality of evidence expected to ↑.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Screening of GC and GPMC</strong></summary>
            <div>
                <ul><li>Suggest against routine screening w/ upper endoscopy for GC &amp; GPMC in general US population (Very low quality of evidence, conditional recommendation).</li><li>Cannot make recommendation on opportunistic screening for GC &amp; GPMC in high-risk individuals (Insufficient evidence, no recommendation).</li></ul>
                
        <details>
            <summary><strong>Risk Factors for GC in US Populations</strong></summary>
            <div>
                <ul><li>US considered low-intermediate GC incidence country overall (ASIR 6.5 per 100,000 person-years).</li><li>Incidence rates 2–13 times higher in certain US populations vs White individuals.</li><li>Multiple factors: precancerous changes, non-White race/Hispanic ethnicity, early-generation immigrant, family history, inherited syndromes, persistent H. pylori, tobacco, possibly AIG.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Race, Ethnicity, and Immigration History</strong></summary>
            <div>
                <ul><li>GC ranks among top 8 causes of cancer death in US Hispanic &amp; Asian American populations.</li><li>Compared to non-Hispanic White individuals, East Asian &amp; Pacific Islander, Black, Hispanic, &amp; AIAN individuals have significantly higher incidence of NCGA.</li><li>NCGA incidence in certain groups (Japanese, Korean Americans) similar/higher than colorectal cancer in general US population.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Family History</strong></summary>
            <div>
                <ul><li>Individuals w/ family history of GC have 2- to 10-fold ↑ risk.</li><li>≈10% GC patients have + family history; 1%–3% related to inherited syndromes.</li><li>Patients w/ GIM &amp; 1st-degree family history of GC had 4.5-fold ↑ odds of GC (OR 4.53, 95% CI 1.33–15.46).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Inherited Cancer Syndromes</strong></summary>
            <div>
                <ul><li>↑ lifetime risk of GC w/ pathogenic variants of GC susceptibility genes.</li><li>Hereditary GC syndromes: hereditary diffuse GC, familial intestinal GC, gastric adenocarcinoma w/ proximal polyposis.</li><li>Hereditary syndromes w/ ↑ GC risk: Lynch syndrome, GI polyposis syndromes, hereditary breast &amp; ovarian cancer syndrome, Li-Fraumeni syndrome, hereditary homologous recombination deficiency (BRCA1, BRCA2, PALB2, ATM).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Screening in High-Risk US Populations</strong></summary>
            <div>
                <ul><li>Routine screening w/ upper endoscopy not indicated in low-risk general US population.</li><li>Lack of evidence in US to make recommendation for focused screening of high-risk populations.</li><li>Evidence base mostly limited to cost-effectiveness studies &amp; indirect evidence from East Asia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>East Asian Studies</strong></summary>
            <div>
                <ul><li>Multiple observational studies from East Asia demonstrated mortality benefits w/ endoscopic GC screening.</li><li>Korean National Cancer Screening Program: endoscopy sensitivity 66%–69%, specificity &gt;99%.</li><li>Organized GC screening associated w/ 47% lower GC mortality (OR 0.53, 95% CI 0.51–0.56).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Meta-analysis by Zhang et al: endoscopic screening associated w/ 40% RR reduction in GC mortality (RR 0.60, 95% CI 0.49–0.73).</li><li>Screening endoscopy associated w/ 2-fold ↑ odds of diagnosing localized GC (OR 2.10, 95% CI 1.90–2.33).</li><li>Implementation of GC screening in Japan &amp; South Korea: ≥50% GC early-stage, 12%–16% metastatic @ diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>US Survival Rates vs. East Asia</strong></summary>
            <div>
                <ul><li>Current 5-year GC survival rate in US is 36%, comparable w/ prescreening implementation rates in South Korea &amp; Japan.</li><li>Systematic screening in high-risk populations associated w/ markedly improved GC mortality &amp; survival.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cost-Effectiveness Studies</strong></summary>
            <div>
                <ul><li>Saumoy et al.: endoscopy starting @ age 45–50 w/ continued surveillance cost-effective for East Asian ($71,451/QALYs), Hispanic ($76,070/QALY), &amp; non-Hispanic Black ($80,278/QALY) individuals.</li><li>Shah et al.: one-time endoscopy @ screening colonoscopy w/ continued surveillance demonstrated lowest incremental cost-effectiveness ratios among Chinese, Japanese, &amp; Korean Americans (&lt;$75,000/QALY).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis of GPMC</strong></summary>
            <div>
                <ul><li>Noninvasive evaluation of GPMC: Suggest against use of noninvasive biomarkers for GPMC/GC screening/surveillance in US (Very low quality of evidence, conditional recommendation).</li><li>Endoscopic evaluation of GPMC: Recommend high-quality endoscopic evaluation of stomach to identify GPMC (Low quality of evidence, strong recommendation).</li></ul>
                
        <details>
            <summary><strong>Noninvasive Biomarkers</strong></summary>
            <div>
                <ul><li>Candidate noninvasive tests: H. pylori IgG, CagA/VacA, pepsinogen I/II, gastrin, C-reactive protein, migration inhibitory factor 1, trefoil factor family 3, reprimo, multiomics.</li><li>Definitive studies lacking regarding efficacy of noninvasive biomarkers for screening/surveillance for GPMC &amp; GC.</li><li>No noninvasive biomarkers replace upper endoscopy or discriminate subjects @ low vs high risk of GPMC, GPMC progression, or GC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Quality Endoscopy Considerations</strong></summary>
            <div>
                <ul><li>Endoscopic &amp; histopathologic evaluations core of GPMC diagnosis &amp; risk stratification.</li><li>Primary goal: early detection of gastric dysplasia &amp; cancer.</li><li>Secondary goal: diagnosis &amp; assessment of severity &amp; extent of AG &amp; GIM.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Indications for Endoscopy</strong></summary>
            <div>
                <ul><li>Individuals warranting endoscopy w/ HDWLE &amp; IEE, systematic biopsy sampling: known GPMC/prior GC w/ indications for surveillance, ↑ risk for GPMC/GC, endoscopic appearance concerning for GPMC.</li><li>High-quality evaluation of entire gastric mucosa foundation for identifying GPMC &amp; GC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Quality Metrics</strong></summary>
            <div>
                <ul><li>Complete mucosal evaluation achieved by insufflation, mucosal cleansing, sufficient time evaluating all gastric areas.</li><li>Mucolytic &amp; defoaming agents improve mucosal visibility scores &amp; reduce total procedure time.</li><li>Quality of visualization should be documented in endoscopic report.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Training</strong></summary>
            <div>
                <ul><li>Training endoscopists to perform detailed gastric evaluation &amp; recognize/classify lesions ↑ detection of GPMC &amp; reduces time to referral.</li><li>Surrogate measures: endoscopic visualization time &amp; photodocumentation.</li><li>GPMC detection rates ↑ after detailed gastric evaluation (e.g., 6–7 minutes) after mucosal cleansing.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Photodocumentation</strong></summary>
            <div>
                <ul><li>Photodocumentation of each gastric station &amp; any abnormal findings important to structure endoscopic examination.</li><li>Protocols recommend photodocumentation of ≥20 stations.</li><li>Advocate for photodocumentation of 6 anatomic stations: 3 antegrade (corpus-greater curvature, corpus-lesser curvature, antrum-pylorus) &amp; 3 retrograde (incisura, corpus-greater curvature, fundus-cardia).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>High-Definition Endoscopy (HD)</strong></summary>
            <div>
                <ul><li>HD defined as image w/ &gt;650 to 720 lines of resolution.</li><li>HDWLE systems offer electronic magnification of ×1.5 or ×2.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Image-Enhanced Endoscopy (IEE)</strong></summary>
            <div>
                <ul><li>Chromoendoscopy achieved w/ topical dyes or virtually w/ modifications of light wavelength or computer image processing (IEE).</li><li>Virtual chromoendoscopy most practical for use in US.</li><li>Optical image processing: narrow band imaging (NBI) from Olympus, Fujinon Intelligent Color Enhancement (BLI, LCI), iScan from Pentax.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recognition and Categorization of GPMC</strong></summary>
            <div>
                <ul><li>Endoscopy identifies GPMC as visible nonpolypoid/polypoid mucosal changes or “nonvisible” mucosal changes.</li><li>Three mucosal changes: AG, GIM, dysplasia.</li><li>Endoscopy alone cannot reliably differentiate between dysplasia &amp; early carcinoma; histologic confirmation needed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HDWLE and IEE</strong></summary>
            <div>
                <ul><li>Suggest using HDWLE &amp; virtual IEE to evaluate gastric mucosa to optimize identification &amp; characterization of GPMC.</li><li>NBI/BLI in stomach has inadequate illumination for wide-field view.</li><li>IEE w/ LCI uses short wavelengths to produce bright images even for distant views.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Normal Gastric Mucosa</strong></summary>
            <div>
                <ul><li>Familiar w/ appearance of normal gastric folds, pit patterns, regular arrangement of collecting venules.</li><li>Gastric folds typically 5–10 mm thick in fundus &amp; body, traverse in parallel, flatten toward antrum.</li><li>Healthy gastric mucosa has round pit patterns in corpus &amp; elongated pit patterns in gastric antrum on HDWLE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Atrophy</strong></summary>
            <div>
                <ul><li>Loss of glandular mass w/ variable lamina propria fibrosis, w/ or w/o replacement by metaplastic tissue (GIM).</li><li>4 hallmark endoscopic findings: pallor, loss of gastric folds, prominence of submucosal vessels, border between atrophic &amp; normal mucosa in HpAG.</li><li>Loss of gastric folds most sensitive change, followed by ↑ visibility of submucosal venules.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Patterns of Gastric Atrophy</strong></summary>
            <div>
                <ul><li>Most examples divided into 2 patterns: HpAG &amp; AIG.</li><li>HpAG develops in gastric antrum &amp; incisura, may extend proximally.</li><li>AIG detected in gastric corpus &amp; fundus w/ characteristic sparing of antrum unless concomitant HpAG.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Intestinal Metaplasia (GIM)</strong></summary>
            <div>
                <ul><li>On HDWLE, GIM appears as irregular, patchy, white mucosa w/ tubulovillous pattern.</li><li>Features of GIM on HDWLE &amp; NBI (or BLI): light blue crest sign, marginal turbid band, “white opaque substance” sign.</li><li>Moderate interobserver reliability of endoscopic findings; improved agreement comes w/ experience.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dysplasia and Early Gastric Cancer (EGC)</strong></summary>
            <div>
                <ul><li>Mucosal changes of dysplasia &amp; EGC nonspecific &amp; subtle.</li><li>Dysplasia manifests either erythema or pallor, slight elevation/depression, thickening, abnormal convergence/flattening of gastric folds, irregular mucosal vessels w/ loss of mucosal architecture.</li><li>Ulcerated lesions often reflect invasive adenocarcinoma.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Histologic Diagnosis of GPMC</strong></summary>
            <div>
                <ul><li>Suggest systematic gastric sampling according to updated Sydney biopsy protocol (Low quality of evidence, conditional recommendation).</li><li>Suggest histological subtype of GIM (incomplete, complete, mixed) be reported for GPMC risk stratification (Low quality of evidence, conditional recommendation).</li></ul>
                
        <details>
            <summary><strong>Gastric Pathology Reporting</strong></summary>
            <div>
                <ul><li>Requires coordination between endoscopist &amp; pathologist.</li><li>Details include stomach location (antrum, corpus), severity &amp; extent of GPMC, subtype of GIM, presence/absence of H. pylori.</li><li>Sydney system: systematic biopsies of 5 sites (greater &amp; lesser curvatures of antrum &amp; corpus, incisura angularis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GIM Subtyping</strong></summary>
            <div>
                <ul><li>Separates GIM into complete &amp; incomplete types.</li><li>Determination readily made on H&amp;E-stained sections.</li><li>Strong, consistent data support GIM subtyping as complete vs incomplete to delineate risk for progression to neoplasia in high-risk populations.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Severity of AG and GIM</strong></summary>
            <div>
                <ul><li>Refers to proportion of atrophy/GIM in individual biopsies in each compartment (antrum, incisura, corpus).</li><li>↑ severity of AG/GIM consistently associated w/ ↑ risk of neoplastic progression.</li><li>OLGA/OLGIM considers extent &amp; severity of AG/GIM; strongly associated w/ risk of progression based on non-US data.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dysplasia</strong></summary>
            <div>
                <ul><li>All samples concerning for dysplasia (IND, LGD, HGD) should be reviewed by expert GI pathologist.</li><li>IND category often applied in presence of obscuring inflammation.</li><li>Ensure causes of inflammation (H. pylori, NSAIDs) addressed &amp; removed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histologic Features of Dysplasia</strong></summary>
            <div>
                <ul><li>LGD: similar to colorectal tubular adenomas, enlarged hyperchromatic nuclei aligned perpendicular to cell basement membranes.</li><li>HGD: loss of nuclear polarity w/ erratic arrangement of enlarged hyperchromatic nuclei.</li><li>Some examples show gastric rather than intestinal type differentiation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of GPMC</strong></summary>
            <div>
                <ul><li>In individuals with GIM who are considered high risk for GC, suggest endoscopic surveillance at 3-year intervals (Very low quality of evidence, conditional recommendation).</li><li>In individuals with severe GIM or AG in biopsies of the antrum or corpus, suggest endoscopic surveillance at 3-year intervals (Very low quality of evidence, conditional recommendation).</li></ul>
                
        <details>
            <summary><strong>Epidemiology of GPMC</strong></summary>
            <div>
                <ul><li>High-risk populations for GPMC parallel high-risk populations for GC.</li><li>AG most common GPMC (≈15% prevalence in US).</li><li>GIM observed in ≈5%–15% patients undergoing upper endoscopy w/ gastric biopsies.</li><li>Prevalence of dysplasia ranges from 0.5% to 3.75%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Factors for GPMC</strong></summary>
            <div>
                <ul><li>Chronic H. pylori infection leading risk factor.</li><li>GPMC more common in non-White individuals &amp; immigrants from high GC incidence regions.</li><li>Additional risk factors: male sex, 1st-degree relative w/ GC, smoking, dietary factors.</li><li>Risk factors for development of GPMC &amp; GC &amp; progression from GPMC to GC overlap.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nondysplastic GPMC and Risk of Progression</strong></summary>
            <div>
                <ul><li>Individuals w/ confirmed GPMC have higher risk of intestinal-type gastric adenocarcinoma.</li><li>10-year cumulative risk of progression to GC among patients w/ histologically confirmed GIM is 1.6% (95% CI 1.5%–1.7%).</li><li>Risk of GC among individuals w/ GPMC varies significantly depending on histological features, anatomic extent, microbial factors, family history, &amp; other factors.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Factors for Progression</strong></summary>
            <div>
                <ul><li>Individuals w/ GIM &amp; additional risk factors for progression have 2.0- to 20-fold ↑ risk of progression to GC.</li><li>Risk factors: corpus-extended AG/GIM, incomplete-type GIM, moderate-severe AG/GIM (OLGA/OLGIM III-IV), family history of GC in 1st-degree relative.</li><li>Some individuals w/ mild GPMC may show regression, particularly after confirmed H. pylori eradication.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histologic Determinants of Nondysplastic GPMC Progression</strong></summary>
            <div>
                <ul><li>Appropriate sampling using Sydney protocol allows determination of anatomic extent, GIM subtype, histopathological stage/severity, presence of H. pylori infection/AIG.</li><li>Corpus-extended GIM has higher risk of progression to GC compared w/ GIM limited to antrum &amp; incisura.</li><li>Unifocal AG/GIM associated w/ lower risk than multifocal AG/GIM.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histologic Severity</strong></summary>
            <div>
                <ul><li>Moderate to severe AG/GIM associated w/ substantially higher risk of GC compared w/ mild AG/GIM.</li><li>OLGA/OLGIM III/IV associated w/ 27.7-fold ↑ RR of GC compared w/ stage 0/I/II (meta-analysis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GIM Subtype</strong></summary>
            <div>
                <ul><li>Several studies report several-fold ↑ risk of progression in patients w/ incomplete-type GIM compared w/ complete-type GIM.</li><li>Meta-analysis: pooled RR of dysplasia &amp; GC of 3.72 (95% CI 1.42–9.72) &amp; 5.16 (95% CI 3.28–8.12), respectively, in patients w/ incomplete-type vs complete-type GIM.</li><li>Presence of only complete-type GIM does not seem to confer higher risk of GC compared w/ patients w/o GIM.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Active H. pylori Infection</strong></summary>
            <div>
                <ul><li>Strongly associated w/ GPMC progression.</li><li>Successful H. pylori eradication may be associated w/ stable histology or even regression.</li><li>Patients w/ refractory H. pylori infection particularly high risk &amp; should be offered surveillance endoscopy @ 3-year interval.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Determinants</strong></summary>
            <div>
                <ul><li>Family history of GC strong risk factor for incident GC among patients w/ nondysplastic GPMC.</li><li>Active tobacco smoking associated w/ higher prevalence of GPMC, possibly progression.</li><li>Other putative markers: microbial dysbiosis, changes in non-H. pylori gastric microbiome, tissue-level molecular changes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dysplastic GPMC and Risk of Progression</strong></summary>
            <div>
                <ul><li>Diagnosis of dysplasia subject to interobserver variability, especially for IND &amp; LGD.</li><li>HGD associated w/ synchronous carcinoma or high rate of progression to invasive carcinoma (47%–100% over 4–48 months).</li><li>IND &amp; LGD have lower rate of progression &amp; may even show regression.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GPMC Regression</strong></summary>
            <div>
                <ul><li>Longitudinal data support observation that GPMC may improve or “regress,” particularly after H. pylori eradication in patients w/ less severe baseline histology.</li><li>Even LGD may show improvement, particularly in setting of H. pylori eradication.</li><li>Sampling error &amp; misclassification significant challenges in studies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Surveillance and Intervals</strong></summary>
            <div>
                <ul><li>Sojourn time of nondysplastic GPMC (AG/GIM) to GC relatively long, allows opportunity for endoscopic surveillance for early gastric neoplasia detection &amp; resection.</li><li>Resection of early gastric neoplasia potentially curative.</li><li>Individual surveillance endoscopy recommendation should be based on patient-physician decision-making, patient comorbidities, &amp; overall prognosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance vs. No Surveillance</strong></summary>
            <div>
                <ul><li>No prospective RCTs evaluating impact of endoscopic surveillance vs no surveillance on important outcomes.</li><li>Non-US observational data support that endoscopic surveillance vs no surveillance associated w/ earlier stage of GC among patients w/ high-risk GPMC.</li><li>Patients w/ low risk for neoplastic progression unlikely to benefit from routine interval endoscopic surveillance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance Intervals</strong></summary>
            <div>
                <ul><li>Optimal surveillance interval not defined, should be determined based on individual risk assessment.</li><li>Microsimulation &amp; cost-effectiveness analyses provide guidance regarding individualized approach.</li><li>Recommend patients w/ GPMC &amp; high-risk features (GIM histology, family history, demography) be considered for endoscopic surveillance @ every 3-year intervals.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Management of Dysplastic GPMC</strong></summary>
            <div>
                <ul><li>In patients with dysplasia (IND, LGD, and HGD) and visible margins, suggest endoscopic resection in clinically appropriate patients (Low quality of evidence, conditional recommendation).</li><li>In patients with dysplasia (IND, LGD, and HGD) without visible margins, suggest a repeat endoscopic evaluation with HDWLE and IEE by an experienced endoscopist (Low quality of evidence, conditional recommendation).</li></ul>
                
        <details>
            <summary><strong>Management Depends On</strong></summary>
            <div>
                <ul><li>Grade of dysplasia, presence &amp; characteristics of visible lesion, status of surrounding mucosa, active H. pylori infection, individual patient considerations.</li><li>Diagnosis of dysplasia generally hinges on confirmation from biopsy sampling.</li><li>Recommend any biopsies concerning for dysplasia be reviewed by expert GI pathologist.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>H. pylori Eradication</strong></summary>
            <div>
                <ul><li>In all patients diagnosed w/ active H. pylori infection, recommend eradication treatment w/ confirmation of eradication.</li><li>Awaiting eradication confirmation should not delay endoscopic management, especially for patients w/ HGD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Referral to High-Volume Center</strong></summary>
            <div>
                <ul><li>If index examination performed by provider w/ limited volume/experience, referral to high-volume center preferred.</li><li>Examination allows repeat visualization, systematic protocol biopsies, repeat evaluation for other neoplasia missed on index exam.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Visible Dysplasia</strong></summary>
            <div>
                <ul><li>Dysplasia can be visible &amp; delineated by areas of nodularity, erythema, pallor, or depression.</li><li>Endoscopic resection serves both diagnostic &amp; therapeutic purposes.</li><li>All patients w/ dysplastic GPMC associated w/ visible lesion amenable to endoscopic resection should be referred for endoscopic resection if medically appropriate.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Resection</strong></summary>
            <div>
                <ul><li>Endoscopic resection of LGD is safe (perforation &amp; bleeding rates &lt;1% &amp; &lt;7%, respectively) &amp; associated w/ reduced rates of progression to HGD or carcinoma.</li><li>Lesions &gt;10 mm, w/ HGD, or depressed lesions more likely to harbor carcinoma &amp; should be resected w/ ESD.</li><li>Expert proficiency requires ≥150 cases in Western training environment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nonvisible Dysplasia</strong></summary>
            <div>
                <ul><li>In patients w/ dysplasia w/o visible lesions, short-interval endoscopy w/ detailed evaluation using HDWLE &amp; IEE recommended.</li><li>Second-look endoscopy should be performed by experienced endoscopist in high-volume center w/ EMR/ESD expertise.</li><li>In patients w/ IND/LGD, second-look should be within 6–12 months &amp; after measures to reduce inflammation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance After Nonvisible Dysplasia</strong></summary>
            <div>
                <ul><li>If high-quality upper endoscopic examination confirms nonvisible dysplasia, patients who are medically appropriate should enter regular endoscopic surveillance.</li><li>Patients w/ nonvisible HGD should undergo endoscopic surveillance in 3–6 months, while for those w/ nonvisible IND or LGD, every 6–12 months reasonable.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nonendoscopic Management of GPMC</strong></summary>
            <div>
                <ul><li>Recommend H. pylori eradication in patients with GPMC (AG, GIM, and dysplasia) and resected EGC to reduce the risk of progression to GC and metachronous EGC, respectively (Moderate quality of evidence, strong recommendation).</li><li>Do not suggest the use of aspirin, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, or antioxidants for individuals with GPMC for the purpose of GC chemoprevention (Very low quality of evidence, conditional recommendation).</li></ul>
                
        <details>
            <summary><strong>H. pylori Eradication</strong></summary>
            <div>
                <ul><li>H. pylori dominant global risk factor for GC.</li><li>H. pylori eradication consistently associated w/ significant reduction of GC incidence &amp; mortality.</li><li>In patients w/ high-risk GPMC, H. pylori eradication serves as adjunct measure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis of H. pylori Eradication</strong></summary>
            <div>
                <ul><li>Meta-analysis by Ford et al: H. pylori eradication associated w/ 46% &amp; 39% risk reductions of GC incidence &amp; mortality, respectively.</li><li>Meta-analysis by Kahn et al: 53% reduction in GC incidence in patients w/ EGC after endoscopic resection.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>US Studies on H. pylori Eradication</strong></summary>
            <div>
                <ul><li>2 independent observational studies from US cohorts demonstrated that H. pylori eradication resulted in substantial &amp; significant risk reduction, albeit delayed (e.g., 8 years post-eradication).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chemoprevention for GPMC</strong></summary>
            <div>
                <ul><li>Apart from H. pylori eradication, chemoprevention of GC for patients w/ GPMC not currently recommended.</li><li>Anti-inflammatory agents &amp; antioxidants may reduce risk of progression.</li><li>Quality prospective trials w/ GC incidence &amp; mortality as primary endpoints lacking.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>General Prevention Measures</strong></summary>
            <div>
                <ul><li>In patients w/ GPMC, general behavioral recommendations warranted related to tobacco &amp; alcohol use, salt intake, &amp; fresh fruit &amp; vegetable consumption.</li><li>Maintaining healthy weight also important.</li><li>Tobacco use may have strongest association w/ GC among behavioral factors; patients w/ GPMC should receive smoking cessation counseling.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Acid Suppression</strong></summary>
            <div>
                <ul><li>Long-term carcinogenic risk related to chronic PPI use unclear.</li><li>Uncertain whether chronic hypochlorhydria due to PPI use &amp; resultant hypergastrinemia ↑ risk of gastric malignancy, particularly in patients w/ GPMC.</li><li>Potassium-competitive acid blockers less studied about association w/ gastric neoplastic risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Special Topics: AIG and Gastric Polyps</strong></summary>
            <div>
                <ul><li>Among individuals diagnosed with AIG, recommend assessment for H. pylori infection with a nonserological test, eradication treatment if positive, and posttreatment testing to confirm eradication (Low quality of evidence, strong recommendation).</li><li>There is insufficient evidence to make a formal recommendation on endoscopic surveillance in individuals with AIG. Given the increased risk of type 1 neuroendocrine tumors (NETs) and the possible increased risk of GC, individualized surveillance may be considered (Low quality of evidence, conditional recommendation).</li></ul>
                
        <details>
            <summary><strong>Autoimmune Gastritis (AIG)</strong></summary>
            <div>
                <ul><li>Immune-mediated condition whereby autoantibodies target &amp; destroy parietal cells.</li><li>Antral-sparing sine qua non of AIG in absence of prior/concurrent H. pylori infection.</li><li>Diagnosis supported by + autoantibodies to parietal cells &amp; intrinsic factor.</li><li>Pernicious anemia rare, late-stage complication.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>AIG as Preneoplastic Condition</strong></summary>
            <div>
                <ul><li>Endoscopic surveillance indicated to allow for early detection &amp; management of neoplasia.</li><li>Ongoing inflammation leads to progressive oxyntic gland loss &amp; replacement of native glands w/ pyloric, intestinal, &amp; pancreatic metaplasia.</li><li>AIG associated w/ well-differentiated NETs of enterochromaffin-like cells (type I gastric carcinoid tumors).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk of Gastric Adenocarcinoma</strong></summary>
            <div>
                <ul><li>In absence of H. pylori infection, risk of gastric adenocarcinoma in patients w/ AIG seems similar to that of baseline general population.</li><li>Prior literature reporting ↑ association did not appropriately control for current H. pylori infection.</li><li>Importance of testing for H. pylori in any patient w/ metaplastic/nonmetaplastic AG.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance in AIG</strong></summary>
            <div>
                <ul><li>No RCTs of surveillance vs no surveillance for early neoplasia detection in patients w/ histologically confirmed AIG.</li><li>Given ↑ risk of gastric NET &amp; possibly gastric adenocarcinoma, endoscopic surveillance suggested in context of shared decision-making.</li><li>Endoscopic surveillance interval should be determined based on same risk stratification factors as described for GPMC in general.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Epithelial Polyps (GEP)</strong></summary>
            <div>
                <ul><li>Recommend endoscopic resection of all gastric adenomas, regardless of size, to exclude and prevent dysplasia and EGC (Low quality of evidence, conditional recommendation).</li><li>Could not make a recommendation on the endoscopic resection of all hyperplastic polyps greater than 10 mm in size based on the current evidence.</li><li>In individuals with GEP, with the exception of fundic gland polyps, recommend systematic gastric biopsies be obtained from the surrounding mucosa (Very low quality of evidence, conditional recommendation).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis of GEP</strong></summary>
            <div>
                <ul><li>GEPs found in ≈3%–10% of EGDs in US; most are incidental fundic gland polyps (FGPs), followed by hyperplastic polyps &amp; gastric adenomas.</li><li>Most GEPs arise in setting of inflammatory conditions (H. pylori gastritis &amp; AIG).</li><li>Biopsy of flat mucosa surrounding gastric polyp &amp; Sydney protocol biopsies indicated, unless polyp clearly FGP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Fundic Gland Polyps (FGPs)</strong></summary>
            <div>
                <ul><li>Sporadic FGPs typically small, hyperemic, sessile, smooth surface contour.</li><li>Occur exclusively in gastric fundus &amp; corpus.</li><li>Occasionally harbor surface dysplasia; risk of progression essentially nil.</li><li>Multiple FGPs (&gt;50) in young patients should raise suspicion for FAP &amp; other polyposis syndromes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hyperplastic Polyps and Adenomas</strong></summary>
            <div>
                <ul><li>Considered premalignant conditions (GPMC).</li><li>Hyperplastic polyps have smooth, red buttered appearance w/ white exudates.</li><li>Associated w/ gastric atrophy w/ or w/o intestinal metaplasia.</li><li>May harbor dysplasia in 1.9%–19% of cases &amp; undergo malignant transformation in up to 2% of cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Adenomas</strong></summary>
            <div>
                <ul><li>Usually single lesions, pedunculated/sessile, in antrum/incisura.</li><li>Most often occur in setting of H. pylori-associated gastric atrophy w/ or w/o metaplasia.</li><li>≈40% harbor dysplastic foci, particularly those ≥20 mm.</li><li>Strongly associated w/ synchronous GC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Management of GEP</strong></summary>
            <div>
                <ul><li>Based on histologic subtype, polyp size, morphologic features.</li><li>Obtaining biopsies from any GEP that is not obvious FGP recommended for histopathological assessment.</li><li>Forceps biopsy can miss foci of HGD or carcinoma; 25% of polyps upgraded after complete excision.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Resection and Surveillance</strong></summary>
            <div>
                <ul><li>Small GEP should be completely excised for both diagnosis &amp; therapy.</li><li>Snare polypectomy suggested for polyps &gt;3 mm.</li><li>Resection &amp; surveillance plan tailored to polyp subtype.</li><li>Excision of FGPs only suggested if polyp &gt;10 mm or ulcerated.</li><li>Adenomas more likely to harbor microscopic carcinoma foci (5%–10% in small case series, up to 50% in polyps ≥20 mm).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusions</strong></summary>
            <div>
                <ul><li>GPMC research agenda extensive, supports implementation, evolution, &amp; optimization of clinical practice in US.</li><li>Critical areas: health outcomes related to GPMC surveillance, screening for GC, barriers to prevention, novel biomarkers, advancement of endoscopic technologies, novel H. pylori treatment, chemoprevention.</li><li>Coordination w/ pathology colleagues imperative.</li></ul>
                
        <details>
            <summary><strong>ACG Guidelines</strong></summary>
            <div>
                <ul><li>ACG Guidelines for management of GPMC paradigm shift in US clinical practice.</li><li>Implementation &amp; change in clinical practice will require concrete targets &amp; include training &amp; quality initiatives.</li><li>Overarching goals: reduce GC incidence, ↑ detection of early stage disease, ↑ 5-year survival rates.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
